-
Oct 21, 2024 | 
outsourcedpharma.com | Louis Garguilo |BioPlan Associates |Ioanna Deni |Anjeanette Ormonde
It’s not magic -- it’s science. With KBI Biopharma’s SUREmAb™ solution, your mAb development moves faster and smarter. Get minimum titers of 4 g/L and up to 10g/L for your IgG monoclonal antibodies before process optimization and tox material in just 6.5 months from transfection—guaranteed. Built on the SUREtechnology Platform™, powered by Selexis®, that has enabled bringing over 110 mAbs to clinic and 7 to market. Set your mAb program on the fast track.
-
Oct 11, 2024 | 
bioprocessonline.com | Ioanna Deni |BioPlan Associates
By Ioanna Deni, BioPlan Associates, Inc.
For over 10 years, downstream bioprocessing (DSP) capacity has been considered an Achilles' heel of biomanufacturing, with purification and separation steps notoriously slowing production. According to the 21st Annual Survey of Biopharmaceutical Manufacturing Capacity and Production, these challenges began as upstream titers coming from bioreactors were increasing and productivity was improving. Downstream innovations were slower to keep up.
-
Oct 7, 2024 | 
bioprocessonline.com | Ioanna Deni |Wen-Rong Jiang |JOINN Biologics
Webinar: The Way Forward: Supply Chain SolutionsJoin us on October 24th as Thermo Fisher Scientific explores supply chain optimization solutions and best practices to avoid disruptions that can lead to material delays and increased costs. Learn how to enhance strategic planning for your critical chemicals and pre-production operations and discover programs that provide cost, time, and resource savings.
-
Oct 3, 2024 | 
biosimilardevelopment.com | Matthew Pillar |Vaibhav Patel |Ioanna Deni
Get more biosimilar development insight with our FREE newsletter
Newsletter
| October 3, 2024
Scale-up in all its iterations from bench to commercial readiness, tech transfer to an outsourced manufacturing partner, product acquisition, and even process development personnel turnover place analytical decisions made early on under a microscope.
-
Sep 6, 2024 | 
bioprocessonline.com | Ioanna Deni
By Ioanna Deni, Bioplan Associates Inc.
The COVID-19 pandemic was a watershed moment for the biomanufacturing industry, not only in terms of the global demand for vaccines and therapeutics but also in the challenges it presented to the suppliers of critical materials and equipment.
-
Sep 6, 2024 | 
advancingrna.com | Ioanna Deni
By Ioanna Deni, Bioplan Associates Inc.
The COVID-19 pandemic was a watershed moment for the biomanufacturing industry, not only in terms of the global demand for vaccines and therapeutics but also in the challenges it presented to the suppliers of critical materials and equipment.
-
Sep 6, 2024 | 
outsourcedpharma.com | Ioanna Deni |Louis Garguilo
By Ioanna Deni, Bioplan Associates Inc.
The COVID-19 pandemic was a watershed moment for the biomanufacturing industry, not only in terms of the global demand for vaccines and therapeutics but also in the challenges it presented to the suppliers of critical materials and equipment.
-
Sep 5, 2024 | 
pharmamanufacturing.com | Ioanna Deni
The COVID-19 pandemic highlighted an important turning point for the adoption of single-use systems (SUS) in biopharmaceutical production. The need for large-scale production of vaccines and therapeutics created extreme pressures to respond quickly and responsibly. Many biomanufacturers responded to the global threat by expanding capacities with SUS technologies.
-
Aug 26, 2024 | 
bioprocessonline.com | Ioanna Deni |Henry George |Daniel C. Teasley |Millipore Sigma
Webinar: Bringing It All Together – Data Harmony in the Bioprocess EcosystemJoin us on September 20th to learn how to achieve seamless data integration within your bioreactor system by unifying information from various sources to gain a holistic view of your cultivation process. Discover how to contextualize bioreactor data using cutting-edge tools to create valuable insights about your cultivation and embrace automation methodologies to free up resources for critical decision-making.
-
Aug 12, 2024 | 
outsourcedpharma.com | Ioanna Deni |Louis Garguilo
Guest Column
| August 12, 2024
By Ioanna Deni, BioPlan Associates Inc.
The adoption of single-use systems (SUS) in biopharmaceutical manufacturing has seen a dramatic change over the years. In 2024, SUS usage rates hit 87%, according to BioPlan’s 21st Annual Report and Survey. Although we have seen steadily increasing acceptance of SUS over the past decades, COVID created an environment where the shift from fixed stainless-steel bioprocessing has accelerated.
